Development of Stability Indicating Methods

  • Anne-Françoise Aubry
  • Peter Tattersall
  • Joan Ruan


The evaluation of the chemical stability studies of small molecule pharmaceuticals rely primarily on the availability of a chromatographic or other separation assay capable of separating and quantifying major impurities and degradation products. A staged approach to the development of stability-indicating HPLC methods, consistent with current regulatory guidelines, is outlined. Practical recommendations are provided for developing forced degradation protocols at every stage of drug development and avoiding common pitfalls that may confuse data interpretation. Consideration is given to special cases such as stereoisomeric drugs, polymorphs, and combination drug products.


High Performance Liquid Chromatographic Drug Product Drug Substance High Performance Liquid Chromatographic Method Pharm Biomed Anal 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Smela M J (2005) Regulatory considerations for stability indicating analytical methods in drug substance and drug product testing. Am Pharm Rev 8:51–54.Google Scholar
  2. 2.
    ICH Q5 (1996) Stability testing of biotechnological/biological products.Google Scholar
  3. 3.
    ICH Q1A (2003) Stability testing of new drug substances and products.Google Scholar
  4. 4.
    ICH Q1E (2003) Evaluation of stability data.Google Scholar
  5. 5.
    ICH Q3A (R) (2003) Impurities in new drug substances.Google Scholar
  6. 6.
    ICH Q3B (R) (2003) Impurities in new drug products.Google Scholar
  7. 7.
    ICH Q6A (2000) Guidance on specifications: test procedures and acceptance criteria for new drug substance and products: chemical substances.Google Scholar
  8. 8.
    ICH Q2A (R) (1995) Guideline for industry, text on validation of analytical procedures.Google Scholar
  9. 9.
    ICH Q2B (R) (1996) Guideline on validation of analytical procedures: methodology.Google Scholar
  10. 10.
    Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG (2002) Available guidance and best practices for conducting forced degradation studies. Pharm Technol 26:48–56.Google Scholar
  11. 11.
    Reynolds DW (2004) Forced degradation of pharmaceuticals. Am Pharm Rev 7:56–61Google Scholar
  12. 12.
    Thatcher SR, Mansfield RK, Miller RB, Davis CW, Baertschi SW (2001) Pharmaceutical photostability: a technical guide and practical interpretation of the ICH guideline and its application to pharmaceutical stability – Part I. Pharm Technol N Am 25:98–110.Google Scholar
  13. 13.
    Baertschi SW (2005) Pharmaceutical stress testing: predicting drug degradation. Taylor & Francis, Boca Raton.Google Scholar
  14. 14.
    FDA (2003) Guidance for industry INDs for phase 2 and 3 studies; chemistry, manufacturing, and control information.
  15. 15.
    Alsante KM, Martin L, Baertschi SW (2003) A stress testing benchmarking study. Pharm Technol 27:60–72.Google Scholar
  16. 16.
    Kats M (2005) Forced degradation studies: regulatory considerations and implementation. BioPharm Int 18:7.Google Scholar
  17. 17.
    Alsante KM, Ando A, Brown R, Ensing J, Hatajika TD, Kong W, Tsuda Y (2007) The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv Drug Deliv Rev 59:29–37.CrossRefPubMedGoogle Scholar
  18. 18.
    Dolan JW (2002) Stability-indicating assays. LCGC N Am 20:346–349.Google Scholar
  19. 19.
    Ruan J, Tattersall P, Lozano R, Shah P (2006) The role of forced degradation studies in stability indicating HPLC method development. Am Pharm Rev 9:46–53.Google Scholar
  20. 20.
    Wen C (2006) Designing HPLC methods for stability indication and forced degradation samples for API. Am Pharm Rev 9:137–140.Google Scholar
  21. 21.
    Baertschi SW, Boccardi G (2005) Oxidative susceptibility testing. In: Baertschi SW (ed) Pharmaceutical stress testing: predicting drug degradation. Taylor & Francis, Boca Raton.Google Scholar
  22. 22.
    Yoshioka S, Stella VJ (2000) Stability of drugs and dosage forms. Kluwer Academic/Plenum Publishers, New York.Google Scholar
  23. 23.
    Stepensky D, Chorny M, Dabour Z, Schumacher I (2004) Long-term stability study of L-adrenaline injections: kinetics of sulfonation and racemization pathways of drug degradation. J Pharm Sci 93:969–980.CrossRefPubMedGoogle Scholar
  24. 24.
    Ali I, Gupta VK, Aboul-Enein HY (2007) Role of racemization in optically active drugs development. Chirality 19:453–463.CrossRefPubMedGoogle Scholar
  25. 25.
    FDA (2007) Guidance for industry ANDAs: pharmaceutical solid polymorphism chemistry, manufacturing, and controls information.
  26. 26.
    Donato EM, Dias CL, Rossi RC, Valente RS, Fröelich PE, Bergold AM (2006) LC method for studies on the stability of lopinavir and ritonavir in soft gelatin capsules. Chromatographia 63:437–443.CrossRefGoogle Scholar
  27. 27.
    Storms ML, Stewart JT (2002) Stability-indicating HPLC assays for the determination of prolocaine and procaine drug combinations. J Pharm Biomed Anal 30:49–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Mohammadi A, Rezanour N, Ansari Dogaheh M, Ghorbani Bidkorbeh F, Hashem M, Walker RB (2007) A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets. J Chromatogr B 846:215–221.CrossRefGoogle Scholar
  29. 29.
    Hou S, Hindle M, Byron P (2001) A stability-indicating HPLC assay method for budesonide. J Pharm Biomed Anal 24:371–380.CrossRefPubMedGoogle Scholar
  30. 30.
    Bashki M, Singh S (2002) Development of validated stability-indicating assay methods-critical review. J Pharm Biomed Anal 28:1011–1040.CrossRefGoogle Scholar
  31. 31.
    Hewitt EF, Lukulay P, Galushko S (2006) Implementation of a rapid and automated high performance liquid chromatography method development strategy for pharmaceutical drug candidates. J Chromatogr A, 1107:79–87.CrossRefPubMedGoogle Scholar
  32. 32.
    Brittain H (1974–2006) Analytical profiles of drug substances and excipients (vol 1 to 33), Elsevier, Amsterdam.Google Scholar
  33. 33.
    Xu Q, Trissel L (2003) Stability-indicating HPLC methods for drug analysis. Pharmaceutical Press, London.Google Scholar
  34. 34.
    Pasha K, Muzeeb S, Basha SJS, Shashikumar D, Mullangi R, Srinivas NR (2006) Analysis of five HMG-Coa reductase inhibitors-atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin : pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomed Chromatogr 20:282–293.CrossRefPubMedGoogle Scholar
  35. 35.
    Snyder L, Kirkland J, Glajch J (1997) Practical HPLC method development. Wiley-Interscience, New York.Google Scholar
  36. 36.
    Ohannesian L, Streeter A (2002) Handbook of pharmaceutical analysis. Marcel Dekker, New York and Dong M (2006) Modern HPLC for practicing Scientists. John Wiley and Sons, Hoboken.Google Scholar
  37. 37.
    Karcher BD, Davies ML, Venit JJ, and Delaney EJ (2004) Multi-dimensional screening and analysis (MDSA): an automated tool for HPLC. Am Pharm Rev 7:62–65.Google Scholar
  38. 38.
    Bashki M, Singh S (2004) ICH guidance in practice: establishment of inherent stability of secnidazole and development of a validated stability-indicating high-performance liquid chromatographic assay method. J Pharm Biomed Anal 36:769–775.CrossRefGoogle Scholar
  39. 39.
    Cameron G, Jackson PE, Gorenstein MV (1993) A new approach to peak purity assessment using photodiode array detection. Chem Aus, 288–289.Google Scholar
  40. 40.
    Bryant DK, Kingswood MD, Belenguer A (1996) Determination of liquid chromatographic peak purity by electrospray ionization mass spectrometry. J Chromatogr A 721:41–51.CrossRefGoogle Scholar
  41. 41.
    Xiao KP, Xiong Y, Liu FZ, Rustum AM (2007) Efficient method development strategy for challenging separations of pharmaceutical molecules using advanced chromatographic technologies. J Chromatogr A, 1163:145–156.CrossRefPubMedGoogle Scholar
  42. 42.
    Polite L (2000) Liquid chromatography: basic overview. In: Miller J, Crowther JB (eds) Analytical chemistry in a GMP environment: a practical guide. John Wiley & Sons, New York.Google Scholar
  43. 43.
    Burana-Osot J, Ungboriboonpisal S, Sriphong L (2006) A stability-indicating HPLC method for medroxyprogesterone acetate in bulk drug and injection formulation. J Pharm Biomed Anal 40:1068–1072.CrossRefPubMedGoogle Scholar
  44. 44.
    Sprangler M, Mularz E (2001) A validated, stability-indicating method for the assay of dexamethasone in drug substance and drug product analyses, and the assay of preservatives in drug product. Chromatographia 54:329–334.CrossRefGoogle Scholar
  45. 45.
    Skrdla PJ, Abrahim A, Wu Y (2006) An HPLC chromatographic reactor approach for investigating the hydrolytic stability of a pharmaceutical compound. J Pharm Biomed Anal 41:883–890.CrossRefPubMedGoogle Scholar
  46. 46.
    Bell F, Dolan JW (2006) On-column sample degradation. LC-GC N Am 24:1184–1190.Google Scholar
  47. 47.
    Lange J, Below E, Thede R (2004) Separate determination of mobile-phase rate constants for reversible reactions. J Liq Chrom Relat Tech 27:715–725.CrossRefGoogle Scholar
  48. 48.
    Zhang J, Miller RB, Jacobus R (1997) Development and validation of a stability-indicating HPLC method for the determination of degradation products in dipyridamole injection. Chromatographia 44:247–252.CrossRefGoogle Scholar
  49. 49.
    DiNunzio JE (1992) Pharmaceutical applications of high-performance liquid chromatography interfaced with fourier transform infrared spectroscopy. J Chromatogr 626:97–107.CrossRefGoogle Scholar
  50. 50.
    Chen W, Zhou P, Wong-Moon KC, Cauchon NS (2007) Identification of volatile degradants in formulations containing sesame oil using SPME/GC/MS. J Pharm Biomed Anal 44:450–455.CrossRefPubMedGoogle Scholar
  51. 51.
    Kazakevich Y, LoBrutto R (2007) HPLC for pharmaceutical scientists. Wiley-Interscience, New York.CrossRefGoogle Scholar
  52. 52.
    Lukulay P, Hokanson G (2005) A perspective on reconciling mass balance in forced degradation studies. Pharm Tech 29:106–113.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Anne-Françoise Aubry
    • 1
  • Peter Tattersall
    • 1
  • Joan Ruan
    • 1
  1. 1.Bristol-Myers Squibb Analytical Research and DevelopmentPrinceton

Personalised recommendations